Financial reports
10-K
2023 FY
Annual report
28 Feb 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
10-Q
2023 Q1
Quarterly report
8 May 23
10-K
2022 FY
Annual report
6 Mar 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
10-Q
2022 Q2
Quarterly report
8 Aug 22
10-Q
2022 Q1
Quarterly report
9 May 22
10-K
2021 FY
Annual report
28 Feb 22
10-Q
2021 Q3
Quarterly report
9 Nov 21
Current reports
8-K
Other Events
12 Mar 24
8-K
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results
28 Feb 24
8-K
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
23 Jan 24
8-K
Inhibrx Reports Third Quarter 2023 Financial Results
9 Nov 23
8-K
Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma
2 Nov 23
8-K
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada
19 Sep 23
8-K
Inhibrx Announces $200 Million Private Placement Financing
29 Aug 23
8-K
Inhibrx Reports Second Quarter 2023 Financial Results
7 Aug 23
8-K
Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency
30 May 23
8-K
Submission of Matters to a Vote of Security Holders
25 May 23
Registration and prospectus
D
$200.00 mm in equity / options / securities to be acquired, sold $200.00 mm, 5 investors
31 Aug 23
S-8
Registration of securities for employees
6 Mar 23
S-8
Registration of securities for employees
1 Mar 22
S-3ASR
Automatic shelf registration
3 Sep 21
S-8
Registration of securities for employees
19 Jan 21
S-8
Registration of securities for employees
19 Aug 20
424B4
Prospectus supplement with pricing info
19 Aug 20
S-1MEF
Registration of additional securities for an S-1
18 Aug 20
8-A12B
Registration of securities on exchange
14 Aug 20
S-1/A
IPO registration (amended)
12 Aug 20
Proxies
DEFA14A
Additional proxy soliciting materials
12 Mar 24
PREM14A
Preliminary proxy related to merger
29 Feb 24
DEFA14A
Additional proxy soliciting materials
6 Feb 24
DEFA14A
Additional proxy soliciting materials
23 Jan 24
DEFA14A
Additional proxy soliciting materials
23 Jan 24
DEFA14A
Additional proxy soliciting materials
13 Apr 23
DEF 14A
Definitive proxy
13 Apr 23
DEFA14A
Additional proxy soliciting materials
13 Apr 22
DEF 14A
Definitive proxy
13 Apr 22
DEFA14A
Additional proxy soliciting materials
28 Apr 21
Other
UPLOAD
Letter from SEC
5 Oct 22
CORRESP
Correspondence with SEC
23 Sep 22
UPLOAD
Letter from SEC
15 Sep 22
EFFECT
Notice of effectiveness
19 Aug 20
CERT
Certification of approval for exchange listing
17 Aug 20
CORRESP
Correspondence with SEC
14 Aug 20
CORRESP
Correspondence with SEC
14 Aug 20
SEC STAFF
SEC staff action: Order
13 Aug 20
SEC STAFF
SEC staff action: Order
6 Aug 20
CORRESP
Correspondence with SEC
5 Aug 20
Ownership
144
Notice of proposed sale of securities
26 Mar 24
4
Kelly Deck
22 Mar 24
144
Notice of proposed sale of securities
22 Mar 24
144
Notice of proposed sale of securities
21 Mar 24
144
Notice of proposed sale of securities
20 Mar 24
4
Brendan P. Eckelman
15 Mar 24
4
Kelly Deck
15 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
4
Brendan P. Eckelman
12 Mar 24